Description
Retatrutide is an investigational triple-receptor agonist designed to activate GLP-1, GIP and glucagon receptors. It has attracted significant research interest because these three signalling pathways are involved in appetite regulation, glucose metabolism, energy expenditure and body-weight regulation.
Retatrutide is being studied primarily in relation to weight reduction and metabolic health. Clinical research has examined its potential effects on appetite suppression, satiety, body-weight reduction, glucose control, insulin sensitivity and cardiometabolic risk markers.
Its glucagon-receptor activity also makes it of interest for research into energy expenditure and lipid metabolism, distinguishing it mechanistically from single- and dual-incretin agonists such as semaglutide and tirzepatide.
Research areas include:
- Body-weight regulation and appetite signalling
- Glucose metabolism and insulin sensitivity
- Energy expenditure and metabolic efficiency
- Lipid and fat metabolism
- Cardiometabolic risk factors
- Obesity and related metabolic conditions
Tides Retatrutide is supplied as a lyophilised research-grade powder, with independent batch testing used to verify identity and purity.
Product information:
- Retatrutide
- GLP-1/GIP/glucagon receptor agonist
- Lyophilised powder
- Purity >99%
- Independently batch tested
- Certificate of Analysis available
- UK dispatched
- For research use only
Reviews
There are no reviews yet.